Teriparatide Acetate
Bone & mineral
A PTH(1–34) analogue with strong randomised evidence for reduced vertebral and nonvertebral fractures in specified high risk osteoporosis populations; authorisation applies to defined finished products, not a generic catalogue material.
An authorisation applies to at least one defined finished product in a stated jurisdiction; it does not apply automatically to this catalogue material.
What is Teriparatide Acetate?
Teriparatide acetate is a synthetic parathyroid hormone fragment (PTH 1 34) peptide used in bone and mineral research focusing on osteoanabolic biology; the catalogue label denotes the acetate salt research material.
Which research context has Teriparatide Acetate been associated with?
Teriparatide Acetate is associated with skeletal and mineral research as a synthetic parathyroid hormone fragment 1 to 34 fragment. Randomised studies of defined teriparatide products in specified high risk osteoporosis populations found fewer vertebral and nonvertebral fractures and increased bone mineral density. Regulatory status, dose, route, formulation and product quality remain product specific; this catalogue material is not, by itself, an authorised finished drug or evidence of clinical equivalence.
What documentation is available for Teriparatide Acetate?
Teriparatide Acetate: Batch documents are not yet linked on this site. For this synthetic PTH (1 34) fragment peptide expected evidence comprises batch identifier and release date; identity by liquid chromatography mass spectrometry/intact mass and sequence confirmation; analytical HPLC/UPLC chromatogram with method and purity specification; peptide content, counterion and residual solvent/water declaration; and potency/assay method used for release testing. No batch documentation is shown as available until the record for that specific item is linked and reviewed.
What determines the storage conditions for Teriparatide Acetate?
Teriparatide Acetate: Storage depends on the documented supplied presentation; as a synthetic PTH 1 34 fragment peptide verify dry/lyophilised versus solution supply, counterion and concentration, solvent or buffer choice, pH stability, container closure compatibility and aggregation propensity that influence chemical and physical stability. No storage instruction is shown as available until the stability record for that specific item is linked and reviewed.